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Abstract: IHL-305 is a PEGylated liposomal formulation of irinotecan (CPT-11). The objective
of this study was to evaluate the factors associated with interpatient variability in the pharmacokinetics and pharmacodynamics of IHL-305 in patients with advanced solid tumors. IHL-305
was administered intravenously once every 4 weeks as part of a Phase I study. Pharmacokinetic
studies of the liposomal sum total CPT-11, released CPT-11, SN-38, SN-38G, 7-ethyl-10-[4N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin, and 7-ethyl-10-[4-amino1-piperidino]-carbonyloxycamptothecin in plasma were performed. Noncompartmental and
compartmental pharmacokinetic analyses were conducted using pharmacokinetic data for sum
total CPT-11. The pharmacokinetic variability of IHL-305 is associated with linear and nonlinear clearance. Patients whose age and body composition (ratio of total body weight to ideal
body weight [TBW/IBW]) were greater than the median age and TBW/IBW of the study had
a 1.7-fold to 2.6-fold higher ratio of released CPT-11 area under the concentration versus time
curve (AUC) to sum total CPT-11 AUC. Patients aged ,60 years had a 1.3-fold higher ratio of
percent decrease in monocytes at nadir to percent decrease in absolute neutrophil count at nadir
as compared with patients aged $60 years. There was an inverse relationship between patient
age and percent decrease in monocytes at nadir, ie, younger patients have a higher percent
decrease in monocytes. Patients with a higher percent decrease in monocytes at nadir have a
decreased plasma exposure of sum total CPT-11. The pharmacokinetics and pharmacodynamics of IHL-305 are consistent with those of other PEGylated liposomal carriers. Interpatient
variability in the pharmacokinetics and pharmacodynamics of IHL-305 was associated with
age, body composition, and monocytes.
Keywords: PEGylated liposome, irinotecan, CPT-11, IHL-305, pharmacokinetics, monocytes

Introduction
IHL-305 is a PEGylated liposomal formulation of irinotecan (CPT-11), a camptothecin
analog that inhibits topoisomerase I and is approved for the treatment of metastatic
colorectal cancer.1–4 The PEGylated liposomal formulation consists of phospholipids
arranged in a bilayer with polyethylene glycol (PEG) covalently bound on the external
surface. Encapsulation of CPT-11 allows for release of the active lactone form into the
tumor over a protracted period of time, which is ideal for a cell cycle-specific drug.1–6
CPT-11 is a prodrug that requires metabolic transformation to the active metabolite,
7-ethyl-10-hydroxy-camptothecin (SN-38), which is approximately 100-fold to 1,000fold more active than the parent drug. SN-38 is further conjugated to form an inactive
glucuronide (SN-38G) by uridine diphosphate glucuronosyltransferases, primarily
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the UGT1A1 isoform. Other identified CPT-11 metabolites
are 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin (APC) and 7-ethyl-10-[4-amino1-piperidino]-carbonyloxycamptothecin (NPC).3,7
The pharmacokinetic disposition of carrier-mediated
agents, such as liposomal agents, is dependent upon the
carrier until the drug is released from the carrier.1 Unlike
small molecule anticancer agents, which are metabolized and
cleared by the liver and kidney, the clearance of liposomes
occurs via the mononuclear phagocyte system (MPS). The
MPS is comprised of monocytes, macrophages, and dendritic cells located primarily within the liver and spleen.8
The uptake of liposomes by the MPS may result in acute
impairment or toxicity in the MPS, which in turn decreases
clearance of PEGylated liposomal agents. Thus, there is
a bidirectional interaction between PEGylated liposomal
anticancer agents and the MPS. PEGylated liposomes are
cleared at a slower rate through the MPS compared with
non-PEGylated liposomes.9 Once the drug is released from
the carrier, the pharmacokinetic disposition of the drug will
be the same as after administration of the noncarrier form of
the drug.4,8 Thus, the pharmacokinetic properties of liposomal
agents are unique, and there may be many factors attributed to
their interpatient variability. Nanoparticle anticancer agents
have higher variability in pharmacokinetic (eg, drug clearance, systemic exposure, distribution) disposition (20–100fold), with potentially higher variability in pharmacodynamic
(antitumor response and toxicity) responses as compared with
small-molecule chemotherapy.10,11 The high interpatient variability in pharmacokinetics and pharmacodynamics threatens
the clinical utility and activity of nanoparticle and liposomal
agents. The factors that may explain the variability in the
pharmacokinetics and pharmacodynamics of encapsulated
and released forms of conventional and PEGylated liposomes
remain unclear, but most likely include the MPS.12–18 Our
group has evaluated factors affecting the pharmacokinetics
and pharmacodynamics of liposomal anticancer agents in
preclinical animal models and in patients.10,11 We were the
first to report a reduced clearance of the liposomal encapsulated forms of PEGylated liposomal doxorubicin (Doxil®)
and CKD-602 (S-CKD602) in patients aged $60 years.18–20
We have also reported that monocytes are more sensitive to
S-CKD602 compared with neutrophils, and the increased
sensitivity is related to the liposomal formulation and not
CKD-602.21,22 These results suggest that monocytes engulf
S-CKD602, which causes the release of CKD-602 from
the liposome and toxicity to the monocytes, and that the
effects are more prominent in patients aged ,60 years.20,22,23
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We were also the first group to report that body composition
alters the pharmacokinetics of PEGylated liposomal agents
in mice and in patients.20 In mice, there was greater exposure
of drug in fat compared with muscle after administration
of S-CKD602, whereas there was greater exposure of drug
in muscle compared with fat after administration of nonliposomal CKD-602.24 In addition, in patients, the exposure of
encapsulated liposomal CKD-602 in plasma after administration of S-CKD602 was inversely related to the ratio of total
body weight (TBW) to ideal body weight (IBW), suggesting
that patients with a larger body composition have greater
distribution of drug to fat which results in lower exposure
in plasma. These results in patients are consistent with our
prior studies in mice.
Based on our previous preclinical and clinical studies
of PEGylated liposomal agents, we hypothesized that age,
body composition, and monocyte changes are fundamental
patient-related factors that alter the pharmacokinetics and
pharmacodynamics of all liposomal, nanoparticle, and conjugated drugs.10,11,18 However, these factors have not been
evaluated for other nanoparticle or liposomal agents in mice
or patients.
The clinical and standard pharmacokinetic results of
the Phase I study of IHL-305 have been published previously.25 IHL-305 was associated with higher interpatient
variability in the pharmacokinetic disposition of sum total
(encapsulated + released) and released CPT-11 compared with
nonliposomal CPT-11.25 However, the factors associated with
the high pharmacokinetic variability of IHL-305 have not been
evaluated. Thus, based on our hypothesis described above,
the objective of this study was to evaluate the factors (ie, age,
body composition, monocytes) associated with interpatient
variability in the pharmacokinetics and pharmacodynamics
of IHL-305 in patients with advanced solid tumors.

Patients and methods
Patients
Written informed consent, approved by the institutional
review board of the Sarah Cannon Research Institute and
Vanderbilt University Medical Center, was obtained from
all patients prior to study entry. Patients aged 18 years or
older with a histologically confirmed malignant solid tumor
for which no known regimen or protocol treatments of higher
efficacy were available were eligible for this study. Pertinent
eligibility criteria included an Eastern Cooperative Oncology Group performance status of 0 to 2 and normal bone
marrow, hepatic, and renal function as defined by the following: absolute neutrophil count (ANC) $1,500 cells/µL,
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platelets $100,000 cells/µL, total bilirubin within normal
institutional limits, aspartate aminotransferase/alanine aminotransferase ratio #2.5× institutional upper limit of normal
(ULN) or #5.0× ULN if liver metastases were present, and
plasma creatinine #1.5× institutional ULN or creatinine
clearance $60 mL/min/1.73 m2 for patients with creatinine
levels above institutional normal. Patients were excluded
from the study for any of the following: prior treatment
with CPT-11; chemotherapy or radiotherapy within 4 weeks
(6 weeks for nitrosoureas or mitomycin C); known brain
metastases; significant cardiac disease including heart failure; a history of myocardial infarction; a history of serious
ventricular arrhythmias. All other eligibility criteria have
been previously reported.25

Dosage and administration
IHL-305 is a formulation of CPT-11 encapsulated in longcirculating PEGylated liposomes. In IHL-305, the PEGylated
liposome bilayer is composed of cholesterol and hydrogenated
soybean phosphatidylcholine, and the surface of the liposomes
is modified with PEG. The mean particle diameter is approximately 100 nm and the drug to lipid mass ratio is 1:4 (0.25 mg
CPT-11 per mg of lipid). The PEGylated liposomal formulation was generated by Terumo Corporation (Tokyo, Japan).
IHL-305 was supplied by Yakult Honsha Corporation (Tokyo,
Japan) in sterile 10 mL light-resistant, single-use glass vials
as a translucent white to pale yellow liquid with a nominal
total CPT-11 concentration of 5 mg/mL. IHL-305 was diluted
25-fold in 5% dextrose or normal saline prior to administration. Prior to administration of the study drug, patients were
premedicated with ondansetron (or an other 5-HT3 inhibitor
should circumstances require) and dexamethasone, according
to each institution’s standard of care.
IHL-305 was administered as a 60-minute intravenous
infusion every 4 weeks. Doses administered (expressed in
mg of CPT-11) were 3.5, 7, 10.5, 14, 28, 33.5, 37, 50, 67, 80,
88, 120, 160, and 210 mg/m2. This Phase I study followed
a standard dose escalation design with patients enrolled in
cohorts of three, with the possibility of extending the cohort
up to six patients depending on the number of dose-limiting
toxicities.26 No intrapatient dose escalation was permitted.
The maximum tolerated dose was defined based on standard
criteria.

Blood counts
ANC and monocyte counts were obtained at least once per
week on cycle 1 of the IHL-305 study. Additional counts were
obtained as clinically required. The percent decrease in ANC
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and monocytes at nadir was calculated using the standard
formula [(pre-value-nadir)/pre-value] ×100.

Sample collection, processing, and
analytical studies
Plasma samples for pharmacokinetic assessment were
obtained from all patients. On cycle 1, blood (5 mL) was
collected in tubes containing sodium heparin at prior to
administration, at the end of the infusion (approximately
1 hour), and at 1.5, 2, 3, 5, 9, 13, and 25 hours after the start
of the infusion for patients treated at ,67 mg/m2 and the
first three patients treated at 67 mg/m2. Additional samples
at 49, 73, 97, 169 (day 7), 192 (day 8), and 216 (day 9) hours
after the start of the infusion were also collected for patients
treated at .67 mg/m2 and the last three patients treated at
67 mg/m2.
The blood samples were centrifuged at 3,000× g for
15 minutes at 4°C to collect the plasma fraction. Plasma samples
were processed to measure sum total (encapsulated + released)
CPT-11 and released CPT-11, SN-38, SN-38G, APC, and
NPC, as previously described.27 The sum total CPT-11,
released CPT-11, SN-38, SN-38G, APC, and NPC concentrations were measured using high-performance liquid
chromatography.28 The total (lactone + hydroxy acid) form of
camptothecin was measured for sum total CPT-11, released
CPT-11, SN-38, SN-38G, APC, and NPC samples. The lower
limit of quantitation of the total form sum total CPT-11,
released CPT-11, SN-38, SN-38G, APC, and NPC were 100,
2, 2, 2, 2, and 2 ng/mL, respectively.

Compartmental pharmacokinetic analysis
Compartmental pharmacokinetic analysis of sum total
CPT-11 after administration of IHL-305 was performed
using WinNonlin (version 5.0.1; Pharsight Corporation,
Mountain View, CA, USA).29 Different pharmacokinetic
model structures were considered to characterize the
disposition of IHL-305 in plasma. In the development of
the model, one-compartment and two-compartment models
with linear and nonlinear (Michaelis-Menten) clearance
were evaluated to describe the plasma disposition of IHL305. The final model structure used for the pharmacokinetic
analysis produced identifiable parameters in all patients
except one.
Pharmacokinetic model parameters for sum total CPT-11
after administration of IHL-305 included the volume of the
central compartment (Vc) and intercompartment rate constants, (k12, k21).29 The elimination rate constant from the central compartment (k10) was used to represent linear clearance.
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For nonlinear clearance, the maximum rate (velocity, Vmax)
and a Michaelis constant (Km) were estimated using the
standard Michaelis-Menten equation described below, where
X1 represents the amount remaining and t is the time after
administration of the study drug.
dX 1
dt

=−

Vmax ⋅ X 1
K m ⋅V1 + X 1

Using standard equations, clearance and elimination
half-life were calculated using parameter estimates from
the models. The area under the IHL-305 plasma concentration versus time curve from 0 to infinity (AUC0–∞) was
calculated using the log trapezoidal method by simulating
the concentration versus time data from each patient using
patient-specific parameters.29 The AUC was also normalized
by dose (AUC/dose).
Evaluation of the goodness of fit and the estimated
parameters was based on the Akaike information criterion,
the precision of the parameter estimates, the random distribution of weighted residuals between measured and predicted
concentrations with respect to time, and the absence of a
significant correlation between independent model para
meters (,0.95).29

Evaluation of factors
The patient’s age, TBW/IBW ratio, and percent decrease
in monocytes at nadir were evaluated as potential factors
associated with the pharmacokinetic variability of IHL-305.
The TBW/IBW ratio was calculated using standard equations
and used as a measure of body composition. These same
factors were evaluated as potential factors associated with
the pharmacodynamic variability of IHL-305.

Statistical analysis
The relationship between TBW/IBW and AUC/dose was
analyzed using multiple linear regression controlling for
age. The relationship between clearance and the percent
decrease in monocytes was analyzed using a simple linear
regression. The relationship between dose-normalized sum
total CPT-11 AUC and the percent decrease in monocytes
was analyzed using simple linear regression. The relationship between the percent decrease in monocytes and age
was analyzed using multiple linear regression controlling for
dose. The percent decrease in monocytes and ANC at nadir
within a patient were compared using the Wilcoxon signed
ranked test. The percent decrease in monocytes and ANC at
nadir in patients aged ,60 and $60 years were compared
using the two-sample t-test. All statistical analyses were
1204
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performed using SAS version 9.2 software (SAS Institute,
Cary, NC, USA).30

Results
Patient characteristics
The characteristics of the 42 patients enrolled in this study
from December 14, 2006 to December 15, 2008 have been
described previously.25 Pharmacokinetic studies of IHL-305
were performed in 39 of these patients with a mean (median,
range) age of 59.3 years (60 years, 41–75 years), and the
majority being female (n=26, 66%).

Linear and nonlinear pharmacokinetic
disposition of IHL-305
The variability in the pharmacokinetic disposition of sum
total CPT-11 was related to linear and nonlinear (saturable) clearance of IHL-305 in patients, which was dosedependent. At doses from 3.5 to 50 mg/m2, the IHL-305
sum total CPT-11 plasma concentration versus time profiles
were best described using a model with linear clearance
in all patients (n=14). At doses from 67 to 210 mg/m2, the
IHL-305 sum total CPT-11 plasma concentration versus
time profiles were best described using a model with linear
(n=16) and nonlinear clearance (n=8). The dose of IHL-305
was significantly higher in patients with nonlinear clearance than in patients with linear clearance (P=0.01). The
dose-normalized sum total CPT-11 AUC in patients with
linear clearance and patients with nonlinear clearance are
presented in Table 1.

Relationship between age, body
composition, and pharmacokinetic
disposition of IHL-305
Based on our previous studies reporting both age and TBW/
IBW ratio affecting the pharmacokinetic disposition of
S-CKD602, we evaluated the relationship between these
two factors and the pharmacokinetic disposition of IHL-305.
The relationship between TBW/IBW and dose-normalized
CPT-11 AUC (AUC/dose) in all patients is presented in
Figure 1. Controlling for age, there was an inverse relationship between TBW/IBW ratio and AUC/dose (R2=0.12,
P=0.41), whereby low TBW/IBW was associated with high
AUC/dose in patients aged ,60 years. The effect of age and
TBW/IBW together on the ratio of released CPT-11 AUC to
sum total CPT-11 AUC in all patients was evaluated using a
bubble chart and is presented in Figure 2. Patients whose age
and TBW/IBW were greater than the median of the study had
a 1.7-fold to 2.6-fold higher ratio of released CPT-11 AUC
to sum total CPT-11 AUC.
International Journal of Nanomedicine 2015:10
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Table 1 Compartmental pharmacokinetic parameters of sum total CPT-11 after IHL-305 in patients with linear and nonlinear
disposition
Parameters

k10
t½a
Vc
CL
k12
k21
Km
Vmax
Sum total AUC/dosee

Units

Linear pharmacokinetic
disposition

Nonlinear pharmacokinetic
disposition

Age ,60 years mean ± SD
(range) n=15

Age $60 years mean ± SD
(range) n=15

All ages mean ± SD
(range) n=8

0.034±0.0077 (0.019–0.047)
21.3±5.6 (14.8–35.8)
1.6±0.55 (1.14–2.86)
0.055±0.027 (0.023–0.12)
–
–
–
–

–

(h-1)
(h-1)
(ng/mL)
(ng/h)

0.031±0.0098 (0.016–0.046)
24.9±8.1 (15.0–43.7)
1.6±0.45 (0.90–2.70)
0.048±0.024 (0.021–0.12)
–
–
–
–

(μg/mL⋅h)/(mg/m2)

12.9±4.9c,d (8.19–27.5)

14.5±4.6c,d (8.29–25.1)

(h-1)
(h)
(L/m2)
(L/h/m2)

11.6±3.8 (7.8–17.0)
1.6±0.36 (1.08–2.12)
–
0.15±0.070b (0.10–0.20)
0.095±0.040b (0.066–0.12)
32.8±31.3 (0.93–92.7)
4.54±3.39 (1.72–11.3)
14.8±5.3d (7.79–23.6)

Notes: t½ is the terminal half-life; estimates are from two patients; sum total CPT-11 AUC normalized by dose in patients with linear disposition was not significantly
different between patients aged $60 and ,60 years (P.0.05); dsum total CPT-11 AUC normalized by dose was not significantly different between patients with nonlinear
disposition and patients with linear disposition who were aged $60 and ,60 years (P.0.05); esum total AUC was calculated from 0 to the last sampling time point; k10 is
the elimination rate constant from the central compartment; Vc is the volume of central compartment; CL is clearance; k12 and k21 are intercompartment distribution rate
constants; Vmax is maximum rate (velocity); Km is a Michaelis constant; CPT-11 is irinotecan; IHL-305 is a PEGylated liposomal formulation of irinotecan.
Abbreviations: AUC, area under the concentration versus time curve; SD, standard deviation; –, not applicable.
a

b

c

Relationship between percent decrease
in monocytes and pharmacokinetic
disposition of IHL-305
Based on our prior studies, the percent decrease in monocytes at
nadir on cycle 1 was used as a surrogate measure of monocyte
function. The relationship between the percent decrease in
monocytes and dose normalized CPT-11 AUC in patients with
linear clearance and nonlinear clearance are presented in Figure
3A and B, respectively. For patients with linear clearance, there
was a statistically significant linear relationship between percent
decrease in monocytes and AUC/dose (P=0.008, R2=0.49),
where high percent decrease in monocytes was associated with

low AUC/dose. However, the relationship between the percent
decrease in monocytes and dose-normalized CPT-11 AUC in
patients with nonlinear clearance was not significant (P=0.37,
R2=0.20) which may be due to saturation of the interaction
between IHL-305 and monocytes.

Neutropenia and monocytopenia
associated with IHL-305
To evaluate the differential effects of IHL-305 on neutrophils
and monocytes, we compared the percent decrease in ANC
90

Age (years)

AUC/dose (µg/mL*h/mg)

80
30.00
25.00
20.00
15.00

60
50
40

10.00

30
0.5

5.00
0.00
0.7

70

1.2

1.7

2.2

2.7

TBW/IBW
Figure 1 Relationship between the ratio of TBW/IBW and dose-normalized IHL305 sum total AUC (AUC/dose). AUC/dose in patients aged ,60 and $60 years are
represented by the solid triangles and open triangles, respectively.
Notes: The best-fit line of the data is represented by the curved solid line (R2=0.12).
After controlling for age, there was an inverse relationship between TBW/IBW and AUC/
dose, with a low TBW/IBW being associated with high AUC/dose in patients aged ,60
years; CPT-11 is irinotecan; IHL-305 is a PEGylated liposomal formulation of irinotecan.
Abbreviations: AUC, area under the concentration versus time curve; TBW/IBW,
total body weight to ideal body weight.
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1.0

1.5

2.0

Ratio of TBW/IBW

2.5

3.0

Figure 2 Relationship between two factors, age, and the ratio of TBW/IBW, and
ratio of released CPT-11 AUC to sum total CPT-11 AUC.
Notes: Patients are divided into four groups according to the median value of age and
TBW/IBW. The size of each circle correlates with ratio of released CPT-11 AUC to sum
total CPT-11 AUC in a patient at the specific age and ratio of true body weight to ideal
body weight. The mean ± standard deviation values for the ratio of released CPT-11
AUC to sum total CPT-11 AUC were 0.0042±0.0028, 0.0038±0.0038, 0.0066±0.0084,
and 0.0025±0.0013 in patients aged ,60 years and TBW/IBW ,1.16, patients
aged $60 years and TBW/IBW ,1.16, patients aged $60 years and TBW/IBW $1.16,
and patients aged ,60 years and TBW/IBW $1.16, respectively; CPT-11 is irinotecan;
IHL-305 is a PEGylated liposomal formulation of irinotecan.
Abbreviations: AUC, area under the concentration versus time curve; TBW/IBW,
total body weight to ideal body weight.
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30.00

y = –0.108x +14.7,
R2=0.49

25.00
20.00
15.00
10.00
5.00
0.00

0

20

40

60

80

Percent decrease in monocytes

100

Sum total CPT-11 AUC/dose
(μg/mL*h/mg)

B

Sum total CPT-11 AUC/dose
(μg/mL*h/mg)

A

16.00

y = –0.0396x +8.56,
R2=0.20

14.00
12.00
10.00
8.00
6.00
4.00
2.00
0.00

0

20

40

60

80

100

Percent decrease in monocytes

Figure 3 Relationship between percent decrease in monocytes and dose normalized CPT-11 AUC (AUC/dose).
Notes: (A, B) Represent the relationship between percent decrease in monocytes and AUC/dose in patients with linear clearance and nonlinear clearance, respectively. The
relationship between AUC/dose and percent decrease in monocytes was best described by a linear relationship in patients with linear clearance (P=0.008, y = -0.108x +14.7,
R2=0.49); CPT-11 is irinotecan; IHL-305 is a PEGylated liposomal formulation of irinotecan.
Abbreviation: AUC, area under the concentration versus time curve.

and monocytes at nadir in the blood of patients administered
IHL-305 on cycle 1. The day of nadir (mean ± standard
deviation) for ANC and monocytes after administration of
IHL-305 was 18.7±7.4 days and 11.2±6.1 days, respectively
(P=0.0006). The extent of neutropenia and monocytopenia following administration of IHL-305 is summarized
in Table 2. After administration of IHL-305, the percent
decrease in ANC and monocytes at nadir were 29%±20% and
42%±24%, respectively (P=0.19) in all patients. The ratio of
percent decrease in monocytes to percent decrease in ANC
at their nadir within a patient was 1.4±1.0.
To evaluate age-related effects on the relationship
between neutropenia and monocytopenia after administration
of IHL-305, we compared the percent decrease in ANC and
monocytes in the blood of patients aged ,60 and $60 years.
Categorizing patients as aged ,60 or $60 years was
based on our previous studies reporting a reduced clearance of PEGylated liposomal anticancer agents in patients
aged $60 years compared with patients aged ,60 years.20
The age (mean ± standard deviation) of patients in groups

aged ,60 and $60 years was 51.4±4.8 years and
67.3±5.2 years, respectively (P,0.001). The extent of neutropenia and monocytopenia following administration of
IHL-305 in patients aged ,60 and $60 years is summarized
in Table 2. The percent decrease in ANC and monocytes
in patients aged ,60 years was 30%±23% and 45%±30%,
respectively (P=0.46). The ratio of percent decrease in
monocytes to percent decrease in ANC within a patient
aged ,60 years was 1.7±1.4. The percent decrease in ANC
and monocytes in patients aged $60 years was 28%±19%
and 40%±20%, respectively (P=0.30). The ratio of percent
decrease in monocytes to percent decrease in ANC within a
patient aged $60 years was 1.2±0.7.

Relationship between age
and pharmacodynamics of IHL-305
The relationship between age and percent decrease in
monocytes at nadir in patients treated at a dose $50 mg/m2
is presented in Figure 4. Patients treated at a dose ,50
mg/m2 were not included because the majority of these

Table 2 Summary of ANC and monocyte decrease at nadir after administration of IHL-305
Units

Monocytes mean ± SD
(range)

All patients
Percent decrease

%

a

Patients ,60 years
Percent decrease

%

b,d

Patients $60 years
Percent decrease

%

c,d

42.0±23.9 (0.0–80.1)

ANC mean ± SD
(range)

Ratio monocytes to
ANC mean ± SD (range)

28.8±20.3 (0.0–84.8)

1.40±0.98 (0.067–4.28)

a

44.7±29.9 (0.0–80.1)

b,e

29.6±22.6 (0.0–84.8)

1.65±1.36 (0.22–4.28)

40.2±20.3 (4.35–71.6)

c,e

28.1±18.9 (0.0–65.3)

1.24±0.68 (0.067–2.35)

Notes: P.0.05 for comparison of percent decrease in monocytes and percent decrease in ANC in all patients; bP.0.05 for comparison of percent decrease in monocytes and
percent decrease in ANC in patients aged ,60 years; cP.0.05 for comparison of percent decrease in monocytes and percent decrease in ANC in patients aged $60 years;
d
P.0.05 for comparison of percent decrease in monocytes in patients aged ,60 years and patients aged $60 years; eP.0.05 for comparison of percent decrease in ANC in
patients aged ,60 years and patients aged $60 years; CPT-11 is irinotecan; IHL-305 is a PEGylated liposomal formulation of irinotecan.
Abbreviations: ANC, absolute neutrophil count; SD, standard deviation.
a
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Dose ≤88 mg/m2, y = –1.27x +120 (R2=0.49)
Dose ≥120 mg/m2, y = –1.64x +158 (R2=0.43)
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Figure 4 Relationship between percent decrease in monocytes and age in all patients
with a dose $50 mg/m2.
Notes: For patients with a dose $50 mg/m2 and #88 mg/m2, individual values are
represented by the solid circles. For patients with a dose $120 mg/m2, individual
values are represented by the open triangles. There was a linear relationship between
the percent decrease in monocytes and age in all patients (R2=0.32), patients with a
dose #88 mg/m2 (R2=0.49), and in patients with a dose $120 mg/m2 (R2=0.43); CPT11 is irinotecan; IHL-305 is a PEGylated liposomal formulation of irinotecan.

patients were not evaluated for monocyte counts. There was
an inverse linear relationship between the percent decrease
in monocytes and age in all patients (R2=0.32, P=0.029), in
patients with a dose #88 mg/m2 (R2=0.49, P=0.121), and
in patients with a dose $120 mg/m2 (R2=0.43, P=0.056),
where in all cases younger patients had a higher percent
decrease in monocytes compared with younger patients.
In addition, the percent decrease in monocytes was lower
in patients with a dose #88 mg/m2 than in those with a
dose $120 mg/m2.

Discussion
Major advances in the use of liposomes, conjugates, and
nanoparticles as vehicles to deliver drugs have occurred
in the past 10 years.4,9,31 Doxil and the albumin-stabilized
nanoparticle formulation of paclitaxel (Abraxane®) are now
approved by the US Food and Drug Administration.32–34 In
addition, there are more than 300 liposomal and nanoparticle
formulations of anticancer agents currently in development.4
This is the first study to identify age, body composition, and
monocyte counts as factors associated with pharmacokinetic
variability of a PEGylated liposomal CPT-11 formulation.
These results are consistent with our prior studies of Doxil
and S-CKD602.19,20
The percent decrease in monocytes was significantly correlated with clearance of sum total CPT-11, where patients
with a higher percent decrease in monocytes at nadir have an
increased clearance of sum total CPT-11. The relationship
between changes in monocytes and the pharmacokinetic
International Journal of Nanomedicine 2015:10

disposition of IHL-305 suggest that the monocytes engulf
liposomal anticancer agents via their phagocytic function as
part of the MPS, which causes the release of drug from the
liposome and subsequent cytotoxicity to monocytes.9,34 There
are two potential explanations for the relationship between
changes in monocytes and the pharmacokinetic disposition
of IHL-305. The first theory is that the monocytes engulf
liposomal anticancer agents via their phagocytic function as
part of the MPS, which causes release of drug from the liposome and subsequent cytotoxicity to monocytes. The second
theory is that the reduction in monocytes after administration
of liposomal agents may also be a result of movement of
monocytes out of the bloodstream and into other MPS organs,
such as the liver and spleen. Additionally, monocytes were
more sensitive to IHL-305 as compared with neutrophils in
our study. This is consistent with our previous study, that the
increased sensitivity is related to the liposomal formulation
and not to the encapsulated drug.35 The overall difference in
monocyte and neutrophil sensitivity to IHL-305 is less than
that reported for S-CKD602. This may be due to CPT-11
being less potent than CKD-602 or due to the different
liposomal formulations used in each product. In our study,
the decrease in monocytes is reversible, monocytopenia
resolved in 2 weeks for most patients, and was not a doselimiting toxicity in our study. However, the long-term effects
of liposomal and other nanoparticles on the function of the
MPS and other parts of the immune system are unknown and
need to be evaluated.
The nonlinear clearance of IHL-305 was associated with
high doses of IHL-305 ($67 mg/m2 CPT-11 or 268 mg/m2
lipid). We previously reported that nonlinear clearance of
S-CKD602 was associated with high doses of S-CKD602
(.1.7 mg/m2 CKD-602 or 15.2 mg/m2 lipid).20 The nonlinear clearance of sum total CPT-11 after administration of
IHL-305 and other nanoparticle agents may be related to
saturation of the clearance capacity of the MPS. The difference in the lipid dose of IHL-305 and S-CKD602 resulting in
saturable clearance of each agent suggests that the lipid dose
is not the predominant factor associated with saturating the
MPS, and that other constituents (eg, number of liposomes
administered) and the patient’s MPS function and capacity
may be more important issues. Age and body composition
were not associated with the pharmacokinetic variability
of IHL-305 in patients with nonlinear clearance, which is
consistent with our prior studies.20
Patients who were younger than 60 years and had a
lean body composition had an increased plasma exposure
of IHL-305. The relationship between body composition
and plasma exposure of IHL-305 in patients is consistent
submit your manuscript | www.dovepress.com
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with our prior studies of S-CKD602 which showed that
patients with a lean body composition had a higher plasma
exposure of S-CKD602.20 Our previous studies in mice also
showed that the distribution of S-CKD602 in fat relative to
muscle is greater compared with nonliposomal CKD-602.24
In addition, overweight mice were reported to express more
macrophages in fat.36 The lower exposure of liposomal
agents in patients with a greater TBW/IBW ratio may be a
result of greater distribution of IHL-305 to adipose tissue
and greater uptake by macrophages in adipose tissue. Thus,
adipose tissue could be considered an MPS-related organ,
similar to the liver and spleen. In addition, studies suggest
that obesity induces an inflammatory state, so patients with a
greater TBW/IBW ratio may have heightened MPS function,
which would result in faster clearance of liposomal agents.37
The influence of age on the pharmacodynamics of PEGylated
liposomal agents has been reported by our group. There
was an inverse relationship between patient age and percent
decrease in monocytes at nadir, with younger patients having
a higher percent decrease in monocytes. This is consistent
with our study of S-CKD602, indicating that an age-related
decrease in the function of monocytes may account for the
reduced uptake and clearance of PEGylated liposomes and
cytotoxicity to monocytes.22
We evaluated factors affecting SN-38 AUC but did not
see any relationship. The lack of a relationship between
SN-38 pharmacokinetics and factors associated with the MPS
and pharmacology of liposomal agents is not unexpected
given that the factors affecting liposomal agents (MPS) and
SN-38 (phase I and II hepatic enzymes) are different. In addition, we evaluated the relationship between CPT-11 AUC
(not dose-normalized) and percent decrease in monocytes.
There was no significant relationship between CPT-11 AUC
and percent decrease in monocytes in patients with linear
clearance or in patients with nonlinear clearance.
IHL-305 exhibits all of the pharmacologic, antitumor,
and cytotoxic advantages of a long-acting, liposomal
anticancer agent.4,25,38,39 The high interpatient variability
in the pharmacokinetics and pharmacodynamics of sum
total IHL-305 was associated with age, body composition,
saturable clearance, and monocyte function. Our data also
suggest that IHL-305 undergoes nonlinear or saturable
clearance at higher doses.25 The clinical significance of
these differences and the factors associated with them need
to be evaluated for IHL-305 and other liposomal and nanoparticle anticancer agents. Ultimately, the best predictor of
the pharmacokinetic and pharmacodynamic variability of
IHL-305 and other liposomal and nanoparticle agents may
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be a phenotypic probe that measures the clearance capacity
of liposomes in individual patients.40 This phenotypic probe
can then be used to individualize the dosages of liposomal
and nanoparticle agents for each patient to achieve a target
exposure and thus reduce the pharmacodynamic variability
of these agents.40 As there are more than 300 nanoparticle
anticancer agents currently in development, as well as
numerous other nanoparticles in development for other diseases, the results of our study may have a wide and long-term
impact on the development of these agents.10,11,18
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